Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling

Wenxin He, Xiankun Cao, Kewei Rong, Xiaojun Chen, Shuai Han, An QinFrontiers in Pharmacology 2021 · DOI

Abstract

Osteolysis resulting from osteoclast overactivation is one of the severe complications of breast cancer metastasis to the bone. Previous studies reported that the anti-cancer agent DZNep induces cancer cell apoptosis but paradoxically activates Akt signaling. We previously found that DZNep enhances osteoclast differentiation via this Akt activation. Therefore, we explored the use of the Akt inhibitor AZD3463 alongside DZNep to ameliorate bone erosion while maintaining anti-cancer efficacy. In vitro and in vivo evaluations demonstrated that this combination inhibits breast cancer cell proliferation, migration, and invasion while simultaneously protecting against tumor-induced bone loss. Our findings suggest that DZNep combined with AZD3463 prevents skeletal complications and inhibits breast cancer progression by suppressing the Akt signaling axis.

Introduction: The Vicious Cycle of Bone Metastasis

Breast cancer has a high affinity for bone metastasis, which often triggers a "vicious cycle." Cancer cells in the bone microenvironment secrete factors that overactivate osteoclasts—cells responsible for breaking down bone. This bone destruction releases growth factors that further fuel tumor progression. Breaking this cycle requires a dual-action therapeutic approach that targets both the tumor cells and the pathological bone remodeling process.

The DZNep-Akt Paradox

DZNep is a promising anti-cancer agent that targets the EZH2 protein. However, its clinical utility in bone metastasis is complicated by an "off-target" effect: it activates the Akt signaling pathway. In osteoclast precursors, this activation accelerates differentiation and bone erosion, potentially worsening the metastatic environment. By introducing AZD3463, a potent Akt inhibitor, we aimed to neutralize this harmful impact on bone health while enhancing DZNep's anti-tumor effects.

Methods and Viability Testing

The researchers employed Bone Marrow-derived Macrophages (BMMs) to study osteoclasts and human/mouse breast cancer lines (MDA-MB-231 and 4T1) for tumor assays. A critical first step was establishing the non-toxic dosage range for the inhibitors using CCK-8 cell viability assays to ensure that observed effects on differentiation or migration were not due to simple cell death.

Figure 1: Cell viability assay for AZD3463 at 24 hours, establishing the safe dosage range (up to 500 nM) for subsequent functional experiments.

Results: Synergistic Suppression of Tumor and Osteoclasts

Reversing Osteoclast Overactivation

In vitro, DZNep alone significantly increased the number of TRAP-positive osteoclasts and the area of bone resorption pits. The addition of AZD3463 (250 nM) effectively reversed these effects, confirming that the pro-osteoclastogenic impact of DZNep is mediated through the Akt pathway.

Enhanced Anti-Tumor Efficacy

The combination treatment significantly reduced breast cancer cell colony formation and invasion compared to monotherapy. In wound healing assays, the combination group showed the slowest rate of migration, indicating a synergistic inhibition of the metastatic phenotype.

Figure 2: Comparative cell viability across treatment combinations over time, illustrating the synergistic impact of DZNep and AZD3463 on cell proliferation.

In Vivo Bone Preservation

In a mouse model of bone metastasis, Micro-CT analysis of the tibiae showed that the combination therapy group maintained significantly higher Bone Volume/Total Volume (BV/TV) and trabecular numbers compared to the DZNep-only group. Histological analysis confirmed the smallest tumor volumes in the combination group, with no observed systemic toxicity in the liver or kidneys.

Conclusion

This study identifies a synergistic drug combination—DZNep and AZD3463—that simultaneously attacks breast cancer cells and prevents the bone destruction typically associated with metastasis. By using the Akt inhibitor AZD3463 to block the paradoxical side effects of DZNep, we successfully inhibited tumor progression and preserved bone integrity in animal models, offering a potential new strategy for managing skeletal complications in breast cancer patients.

Summary updated

Abstract

Osteolysis resulting from osteoclast overactivation is one of the severe complications of breast cancer metastasis to the bone. Previous studies reported that the anti-cancer agent DZNep induces cancer cell apoptosis by activating Akt signaling. However, the effect of DZNep on breast cancer bone metastasis is unknown. We previously found that DZNep enhances osteoclast differentiation by activating Akt. Therefore, we explored the use of the anti-cancer agent AZD3463 (an Akt inhibitor) along with DZNep, as AZD3463 can act as an anti-cancer agent and can also potentially ameliorate bone erosion. We evaluated osteoclast and breast cancer cell phenotypes and Akt signaling <i>in vitro</i> by treating cells with DZNep and AZD3463. Furthermore, we developed a breast cancer bone metastasis animal model in mouse tibiae to further determine their combined effects <i>in vivo</i>. Treatment of osteoclast precursor cells with DZNep alone increased osteoclast differentiation, bone resorption, and expression of osteoclast-specific genes. These effects were ameliorated by AZD3463. The combination of DZNep and AZD3463 inhibited breast cancer cell proliferation, colony formation, migration, and invasion. Finally, intraperitoneal injection of DZNep and AZD3463 ameliorated tumor progression and protected against bone loss. In summary, DZNep combined with AZD3463 prevented skeletal complications and inhibited breast cancer progression by suppressing Akt signaling.
BibTeX
@inproceedings{he2021combination,
  author = {Wenxin He and Xiankun Cao and Kewei Rong and Xiaojun Chen and Shuai Han and An Qin},
  title = {{Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.652071},
}
Figure